AFFiRiS develops tailor-made peptide vaccines for alzheimer's, parkinson's, atheroclerosis, hypertension and several other conditions.
AFFiRiS is an Austrian clinical-stage biotechnology company developing therapies for neurodegenerative and chronic diseases. Its Specific Active ImmunoTherapy (SAIT) approach is based on peptide vaccines, with research areas including Alzheimer's, Parkinson's and hypercholesterolemia.
AFFiRiS was founded in 2003 by Frank Mattner, Walter Schmidt.
Source: Crunchbase.
AFFiRiS may be growing as it is listed among companies in the atherosclerotic cardiovascular disease market, which is expected to observe impressive growth at a CAGR of 2.2% by 2032. The company is also mentioned in the context of innovation in pharmaceuticals, specifically in neurodegenerative disease therapies, indicating a recognition in the field of research and development. Furthermore, AFFiRiS is included in a list of companies in the Huntington's disease market, which suggests an expansion of its therapeutic portfolio and potential involvement in growing market segments.
Source: Crunchbase growth insight.
“We are a clinical‑stage biotechnology company striving to deliver novel therapies to patients with neurodegenerative diseases” affiris.com
Source: company website, checked 2026-10-26.
Search verified work emails and direct dials for people at affiris.com.
Or explore the full B2B database and filter by biotechnology companies.